IP Library Granted Patent US 10,632,251
Granted Patent B2
US 10,632,251 · App. 15/674,421 · Granted Apr 28, 2020

Device, system and methods for the oral delivery of therapeutic compounds

Inventors: Mir A. Imran (Los Altos Hills, CA); Peter Herrmann (San Jose, CA); Baber Syed (Palo Alto, CA); Timothy H. Williams (Campbell, CA); Chang Jin Ong (Fremont, CA); Greg Method (San Jose, CA)
Assignee: Rani Therapeutics, LLC
A61M5/155A61K38/13A61K38/21A61K38/26A61K38/27A61K38/28A61K38/29A61K38/30A61K38/55A61M5/14244A61M31/002A61K9/4808A61M37/0069A61M2205/3331A61M2210/1042
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,632,251
App. No.
15/674,421
Granted
Apr 28, 2020
Kind
B2
Abstract

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to a delivery mechanism having one or more balloons or other expandable devices which are expandable responsive to a condition in the small intestine or other GI lumen to advance the preparation out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Claims (16)

1. An ingestible device suitable for swallowing into a lumen of a gastrointestinal tract of a patient, the lumen having a lumen wall, the device comprising:

a capsule sized to pass through the gastrointestinal tract;

an antibody preparation disposed within the capsule, the preparation comprising particles of an antibody which would lose binding affinity or specificity to a target antigen site if released within the lumen of the gastrointestinal tract;

at least one tissue penetrating member disposed within the capsule and operatively coupled to the antibody preparation, the at least one tissue penetrating member configured to be advanced into the lumen wall of the gastrointestinal tract by the application of force on the at least one tissue penetrating member;

an expandable member disposed within the capsule and having a first configuration and a second configuration, the expandable member having a first compartment and a second compartment separated by a release valve configured to release upon exposure to fluid in the gastrointestinal tract, a first reactant contained in one of the compartments and a second reactant contained in the other compartment, the reactants configured to mix to upon release of the release valve so as to produce a gas which expands the expandable member to the second configuration; and

a delivery member for advancing the at least one tissue penetrating member into the lumen wall, the delivery member operably coupled to the expandable member and the at least one tissue penetrating member,

wherein the antibody preparation and the at least one tissue penetrating member are retained within the capsule in the first configuration, and in the second configuration, the delivery member applies a force onto the at least one tissue penetrating member to advance the antibody preparation from the capsule into the lumen wall by motion of the at least one tissue penetrating member, and wherein the binding affinity of the antibody delivered into the lumen wall is preserved.

2. The device of claim 1 , wherein the at least one tissue penetrating member is fluidically coupled to the expandable member by a manifold.

3. The device of claim 1 , wherein the delivery member comprises a piston or a plunger.

4. The device of claim 1 , wherein the antibody is a HER2 antibody.

5. The device of claim 1 , wherein the antibody is for treatment of an autoimmune disease.

6. The device of claim 5 , wherein the antibody is Adalimumab.

7. The device of claim 1 , wherein the antibody is Infliximab.

8. The device of claim 1 , wherein the antibody is Etanercept.

9. The device of claim 1 , wherein the antibody is Natalizumab.

10. The device of claim 1 , wherein the particles of the antibody are micronized.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 19, 2025
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: RANI THERAPEUTICS, LLC
Reel/Frame 073971/0117 →
SECURITY INTEREST Recorded Aug 9, 2022
From: RANI THERAPEUTICS, LLC
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 061131/0478 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2018
From: IMRAN, MIR; HERRMANN, PETER; SYED, BABER; WILLIAMS, TIMOTHY H.; ONG, CHANG JIN; METHOD, GREG
To: INCUBE LABS, LLC
Reel/Frame 045960/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2018
From: INCUBE LABS, LLC
To: RANI THERAPEUTICS, LLC
Reel/Frame 045960/0911 →
Continuity (7)
Continuation 14244673 · Apr 3, 2014
Continuation 13837025 · Mar 15, 2013
Continuation In Part 13532589 · Jun 25, 2012
Continuation In Part 12978301 · Dec 23, 2010
Continuation In Part 12978233 · Dec 23, 2010
Provisional Application 61571641 · Jun 29, 2011
Related Publication 20180008771A1 · Jan 11, 2018
Cited By (6)
US 12,263,325 US 12,268,831 US 12,268,832 US 12,642,947 US 12,653,992 US 12,678,605